Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Common Equity data on file, last reported at $87.8 million in Q1 2026.

• Common Equity for Q1 2026 came in at $87.8 million, down 47.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.8 million (down 47.95% YoY), and the FY2025 annual result was $110.0 million, down 41.08% from the prior year.
• Common Equity fell to $87.8 million in Q1 2026 per ARTV's latest filing, from $110.0 million in the prior quarter.
• Over five years, Common Equity peaked at $201.0 million in Q3 2024 and troughed at -$191.1 million in Q2 2024.
• A 4-year average of $15.8 million and a median of $98.9 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity jumped 232.71% in 2024, then slumped 47.95% in 2026.
• A 4-year view of Common Equity shows it stood at -$162.0 million in 2023, then soared by 215.2% to $186.6 million in 2024, then plunged by 41.08% to $110.0 million in 2025, then decreased by 20.12% to $87.8 million in 2026.
• Business Quant data shows ARTV's Common Equity at $87.8 million in Q1 2026, $110.0 million in Q4 2025, and $129.2 million in Q3 2025.